Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway

Chuan Li1, Xi Yang1, Cheng Chen1

  • 1Department of Gastrointestinal Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.

Molecular Medicine Reports
|January 9, 2014
PubMed

Insights

Isorhamnetin, a flavonoid from medicinal plants, effectively inhibits colorectal cancer (CRC) cell proliferation. It works by blocking the PI3K-Akt-mTOR pathway, showing potential as a novel CRC treatment.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Flavonoids, like isorhamnetin found in Hippophae rhamnoides L., exhibit anticancer properties.
  • The specific impact of isorhamnetin on colorectal cancer (CRC) and its molecular mechanisms remain largely uninvestigated.

Purpose of the Study:

  • To investigate the antiproliferative effects of isorhamnetin on human CRC cell lines (HT-29, HCT116, SW480).
  • To elucidate the molecular pathways targeted by isorhamnetin in CRC cells.

Main Methods:

  • Treatment of HT-29, HCT116, and SW480 cells with isorhamnetin.
  • Cell cycle analysis to determine phase arrest.
  • Western blot analysis to assess protein expression and phosphorylation levels within the PI3K-Akt-mTOR pathway.

Main Results:

  • Isorhamnetin significantly suppressed proliferation across all tested CRC cell lines.
  • The compound induced cell cycle arrest at the G2/M phase.
  • Inhibition of the PI3K-Akt-mTOR pathway was observed, with reduced phosphorylation of Akt, p70S6 kinase, and 4E-BP1, alongside increased Cyclin B1 expression.

Conclusions:

  • Isorhamnetin demonstrates selective inhibition of the PI3K-Akt-mTOR pathway in CRC cells.
  • This flavonoid exhibits potential as a therapeutic agent for colorectal cancer by restraining cancer cell proliferation.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

12.4K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.4K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K